Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of BLS_ILB_E710c for the Fertile Women With Cervical Intraepithelial Neoplasia(CIN3)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Pre-menopausal patients between age of 20 and 50.~* Patients with cervical intraepithelial neoplasia 3(CIN3).~* Only infection with HPV type 16.~* Patients with Capable of observation of all of lesions by Colposcopy biopsy.~* Be informed of the nature of the study and will give written informed consent.~* Be agree with contraception during study~* White Blood Cell Count(WBC) over 4thous/ul, Hemoglobin above over 9.0g/dL Platelet over 150thous/uL and ANC(Absolute Neutrophil Count) over 1,500 /mm\^3~* Normal for EKG(Electrocardiography)~* AST/ALT : 2.5 times less than normal range~Exclusion Criteria:~* Autoimmune Disease or Prohibited drug(Therapy) bring about immunosuppressive.~* Patient that has medical history of hypersensitivity about Food containing Lactic acid bacteria or Lactic acid bacteria medication.~* Patient with Acute illness(ex. Acute Appendicitis, Myocardial infarction, Hemorrhage, meningitis etc.)~* Investigational product within three months before the start of the drug administration to patients treated with other test drug.~* Patient with Chronic pancreatitis currently or Patients diagnosed with acute pancreatitis.~* Organopathy Patient with Inflammatory intestine·bowel disease, gastrointestinal tumors, ulcers, bleeding, perforation etc.~* Pregnant or lactating women~* Patient with HBV or HCV infection (except for Asymptomatic)~* Patient that Investigator judge~* Deemed inappropriate for researchers to judge the patient

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- BLS_ILB_E710c 500mg (Type: EXPERIMENTAL): * Drug: BLS_ILB_E710c 500mg~* Dosage and duration: 2 capsules per day for 20 days (week 1,2,4 \& 8)
- BLS_ILS_E710c 1000mg (Type: EXPERIMENTAL): * Drug: BLS_ILS_E710c 1000mg~* Dosage and duration: 4 capsules per day for 20 days (week 1,2,4 \& 8)
- BLS_ILS_E710c 1500mg (Type: EXPERIMENTAL): * Drug: BLS_ILS_E710c 1500mg~* Dosage and duration: 6 capsules per day for 20 days (week 1,2,4 \& 8)

Based on this trial design, predict the completion outcome and termination type (if applicable).